Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Headache, Inappropriate schedule of product administration, Lymphadenopathy, Oral herpes
Clinical narrative: prev dose administration date 24Feb2021, prev dose dose number=1, prev dose administration date 25Feb2021, prev dose dose number=2,; Headache; chills; swollen lymph nodes under left arm/swolllen neck lymph nodes; fever blisters; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 66 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 25Feb2021 (Lot number: Unknown) at the age of 65 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "Atrial runs and trigeminal neuralgia" (unspecified if ongoing); "Atrial runs and trigeminal neuralgia" (unspecified if ongoing). Concomitant medication(s) included: DILTIAZEM; GABAPENTIN; OXCARBAZEPINE; BUPROPION. Past drug history included: Augmentin, reaction(s): "Known Allergy: Augmentin", notes: known allergies:Augmentin; Clindamycin, reaction(s): "Known Allergy: clindamycin", notes: known allergies:clindamycin. Vaccination history included: Bnt162b2 (Dose Number: 1, Batch/Lot No: Unknown. Not available/provided to reporter at the time of report completion, Location of injection: Arm Left), administration date: 24Feb2021, when the patient was 65 years old, for Covid-19 Immunization. The following information was reported: INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (non-serious) with onset 21Jan2022, outcome "unknown", described as "prev dose administration date 24Feb2021, prev dose dose number=1, prev dose administration date 25Feb2021, prev dose dose number=2,"; HEADACHE (non-serious) with onset 21Jan2022, outcome "not recovered", described as "Headache"; CHILLS (non-serious) with onset 21Jan2022, outcome "not recovered", described as "chills"; LYMPHADENOPATHY (non-serious) with onset 21Jan2022, outcome "not recovered", described as "swollen lymph nodes under left arm/swolllen neck lymph nodes"; ORAL HERPES (non-serious) with onset 21Jan2022, outcome "not recovered", described as "fever blisters". Therapeutic measures were not taken as a result of inappropriate schedule of product administration, headache, chills, lymphadenopathy, oral herpes.  Additional information: Vaccine Facility type was Pharmacy or Drug Store. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient received Diltiazem, gabapentin, oxcarbazepine, and bupropion within 2 weeks of vaccination. Adverse event did not require a visit to Emergency Room/Physician Office. Prior to vaccination, the patient was not diagnosed with COVID-19; Since the vaccination, the patient has not been tested for COVID-19. Known allergies to Augmentin and clindamycin. Other medical history included Atrial runs and trigeminal neuralgia. The patient also received third dose of Pfizer BioNTech COVID-19 vaccine in arm left on 20Jan2022 at 01:15 PM as dose 3( booster) single for Covid-19 immunisation.  The lot number for bnt162b2 was not provided and will be requested during follow up.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202200148526 similar report from same reporter